SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-237990
Filing Date
2022-09-02
Accepted
2022-09-02 17:15:37
Documents
13
Period of Report
2022-08-29
Items
Item 1.02: Termination of a Material Definitive Agreement
Item 1.03: Bankruptcy or Receivership
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K d322264d8k.htm   iXBRL 8-K 38004
  Complete submission text file 0001193125-22-237990.txt   199270

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA alna-20220829.xsd EX-101.SCH 3244
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE alna-20220829_def.xml EX-101.DEF 13819
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE alna-20220829_lab.xml EX-101.LAB 22722
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE alna-20220829_pre.xml EX-101.PRE 14677
7 EXTRACTED XBRL INSTANCE DOCUMENT d322264d8k_htm.xml XML 5211
Mailing Address 142 -F NORTH ROAD, SUITE 150 SUDBURY MA 01776
Business Address 142 -F NORTH ROAD, SUITE 150 SUDBURY MA 01776 617-467-4577
Allena Pharmaceuticals, Inc. (Filer) CIK: 0001624658 (see all company filings)

IRS No.: 452729920 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38268 | Film No.: 221226077
SIC: 2836 Biological Products, (No Diagnostic Substances)